US 12,240,917 B2
Anti-complement C1s antibodies and uses thereof
Peter Van Vlasselaer, Portola Valley, CA (US); Graham Parry, Burlington, MA (US); Nancy E. Stagliano, South San Francisco, CA (US); and Sandip Panicker, South San Francisco, CA (US)
Assigned to Bioverativ USA Inc., Waltham, MA (US)
Filed by Bioverativ USA Inc., Waltham, MA (US)
Filed on Dec. 10, 2021, as Appl. No. 17/548,135.
Application 17/548,135 is a continuation of application No. 16/561,202, filed on Sep. 5, 2019, abandoned.
Application 16/561,202 is a continuation of application No. 15/385,735, filed on Dec. 20, 2016, granted, now 10,450,382.
Application 15/385,735 is a continuation of application No. 14/932,174, filed on Nov. 4, 2015, granted, now 9,562,092.
Application 14/932,174 is a continuation of application No. 14/709,277, filed on May 11, 2015, granted, now 9,206,259.
Application 14/709,277 is a continuation of application No. 14/523,093, filed on Oct. 24, 2014, granted, now 9,074,004.
Application 14/523,093 is a continuation of application No. 14/070,186, filed on Nov. 1, 2013, granted, now 8,945,562.
Claims priority of provisional application 61/846,402, filed on Jul. 15, 2013.
Claims priority of provisional application 61/779,180, filed on Mar. 13, 2013.
Claims priority of provisional application 61/754,123, filed on Jan. 18, 2013.
Claims priority of provisional application 61/721,916, filed on Nov. 2, 2012.
Prior Publication US 2022/0204647 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A01N 1/02 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61K 49/16 (2006.01); A61K 51/10 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/40 (2013.01) [A01N 1/021 (2013.01); A61K 49/00 (2013.01); A61K 49/16 (2013.01); A61K 51/10 (2013.01); C07K 16/18 (2013.01); C12Y 304/21042 (2013.01); G01N 33/6893 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); G01N 2800/52 (2013.01)] 13 Claims
 
1. A humanized antibody that binds complement C1s protein and comprises:
a light chain variable region that comprises a CDR-L1 amino acid sequence set forth as SEQ ID NO: 32, a CDR-L2 amino acid sequence set forth as SEQ ID NO: 33, and a CDR-L3 amino acid sequence set forth as SEQ ID NO: 3;
a heavy chain variable region that comprises a CDR-H1 amino acid sequence set forth as SEQ ID NO: 34, a CDR-H2 amino acid sequence set forth as SEQ ID NO: 35, and a CDR-H3 amino acid sequence set forth as SEQ ID NO: 36; and
a human IgG4 constant region, wherein the human IgG4 constant region comprises a S241P substitution (by Kabat numbering) and an L235 E substitution (by EU numbering).